<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00567047</url>
  </required_header>
  <id_info>
    <org_study_id>CLAF237A2115</org_study_id>
    <nct_id>NCT00567047</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment</brief_title>
  <official_title>An Open-Label, Parallel-Group Study to Determine the Single and Multiple Dose Pharmacokinetics of Vildagliptin and Its Metabolites in Mild, Moderate or Severe Renal Impaired Patients Compared to Age, Sex and Weight-Matched Healthy Volunteers Following Daily Doses of 50 mg Vildagliptin for 14 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacokinetics of vildagliptin and its metabolites in patients&#xD;
      with mild, moderate or severe renal impairment and healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Pharmacokinetic measures</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Safety and tolerability measures</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Type-2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vildagliptin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vildagliptin</intervention_name>
    <arm_group_label>1</arm_group_label>
    <other_name>LAF237</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (general):&#xD;
&#xD;
          -  Men and women (age 18 to 85 years)&#xD;
&#xD;
          -  Participants must be nonfertile or using a medically approved birth control method.&#xD;
             Additional information regarding this requirement available at screening&#xD;
&#xD;
          -  Body mass index (BMI) ≤42 kg/m2 (inclusive)&#xD;
&#xD;
        Inclusion Criteria (for renal insufficient patients):&#xD;
&#xD;
          -  Patients with mild, moderate, or severe kidney impairment. Please consult with&#xD;
             participating physicians regarding the definitions of these levels of severity.&#xD;
&#xD;
          -  Patients with diabetes must be treated with standard anti-diabetic therapy (diet and&#xD;
             exercise, stable dose of sulfonylurea, insulin, or metiglinides) and agree to continue&#xD;
             for the study duration&#xD;
&#xD;
        Inclusion Criteria (for healthy subjects):&#xD;
&#xD;
          -  No current significant medical conditions as determined by history and physical.&#xD;
&#xD;
          -  Serum creatinine with a calculated creatinine clearance (CrCl) of &gt;80 ml/min.&#xD;
&#xD;
          -  Matched to renal impaired patients in the study by age (±5 years), sex and weight&#xD;
             (±10% BMI)&#xD;
&#xD;
          -  Vital signs guided by the following ranges:&#xD;
&#xD;
        oral body temperature between 35.0-37.2 °C systolic blood pressure, 100-140 mm Hg diastolic&#xD;
        blood pressure, 60-110 mm Hg pulse rate, 45-90 bpm&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Pregnant or lactating female.&#xD;
&#xD;
          -  A history of type 1 diabetes, diabetes that is a result of pancreatic injury, or&#xD;
             secondary forms of diabetes, acute metabolic diabetic complications (eg, ketoacidosis&#xD;
             or hyperosmolar state (coma))&#xD;
&#xD;
          -  Subjects that have been enrolled in previous vildagliptin studies or other DPP&#xD;
&#xD;
          -  4 inhibitor studies within six months&#xD;
&#xD;
          -  History of renal transplant or immunosuppressant therapy&#xD;
&#xD;
          -  Acute infections which may affect blood glucose control or other medical condition&#xD;
             that may interfere with the interpretation of efficacy and safety data during the&#xD;
             study&#xD;
&#xD;
          -  Any pre-existing or history of diabetic ulcer&#xD;
&#xD;
          -  Any of the following within the past 6 months: myocardial infarction (MI), coronary&#xD;
             artery bypass surgery or percutaneous coronary intervention, unstable angina or stroke&#xD;
&#xD;
          -  Any of the following electrocardiogram (ECG) abnormalities: Torsades de pointes,&#xD;
             sustained and clinically relevant ventricular tachycardia or ventricular fibrillation,&#xD;
             second degree atrioventricular (AV) block (Mobitz 1 and 2), third degree AV block,&#xD;
             prolonged QTc (&gt;500 ms)&#xD;
&#xD;
          -  Malignancy including leukemia and lymphoma within the last 5 years.&#xD;
&#xD;
          -  Liver disease such as cirrhosis or positive hepatitis B and C.&#xD;
&#xD;
          -  Any alcohol related hepatic disease.&#xD;
&#xD;
          -  Patients undergoing any method of dialysis&#xD;
&#xD;
          -  Use of some concomitant medications&#xD;
&#xD;
          -  Significant laboratory abnormalities as specified in the protocol&#xD;
&#xD;
          -  History of active substance abuse (including alcohol) within the past 2 years.&#xD;
&#xD;
          -  Smokers (i.e., 10 or more cigarettes per day)&#xD;
&#xD;
          -  History of hypersensitivity to any of the study drugs or to drugs with similar&#xD;
             chemical structures&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novartis investigative site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigator Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>December 3, 2007</study_first_submitted>
  <study_first_submitted_qc>December 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2007</study_first_posted>
  <last_update_submitted>March 24, 2009</last_update_submitted>
  <last_update_submitted_qc>March 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Novartis</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

